Business Analysis of Mylan

 Analyze Historical Performance, Strategic Priorities, And Business Improvement Opportunities of Mylan

Business Overview

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, brand name, and over-the-counter products worldwide. The company operates through three segments: North America, Europe, and Rest of World. It offers pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized, and cream or ointment forms. The company also manufactures and sells a portfolio of injectable products across various therapeutic areas, including respiratory and allergy, infectious disease, cardiovascular, oncology, and central nervous system and anesthesia; active pharmaceutical ingredients; antiretroviral therapy products for people living with HIV/AIDS; and products in the therapeutic categories, such as hepatology and critical care. In addition, it provides EpiPen Auto-Injector, which is used to treat severe allergic reactions; Perforomist Inhalation Solution, a formoterol fumarate inhalation solution for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder patients; ULTIVA, an analgesic agent used during the induction and maintenance of general anesthesia for inpatient and outpatient procedures; and Dymista, which is used for the treatment of seasonal allergic rhinitis. The company markets its products to wholesalers, distributors, retail pharmacy chains, mail order pharmacies, and group purchasing organizations; and independent pharmacies, managed care organizations, hospitals, nursing homes, and pharmacy benefit managers. The company was formerly known as New Moon B.V. Mylan N.V. was founded in 1961 and is based in Hatfield, the United Kingdom.

Mylan

Mylan


R&P Rank: 263
Sector: Life Sciences
Industry:Pharmaceuticals
H.Q Location:Not In U.S.A.
Website: www.mylan.com
Company Address:
BUILDING 4, TRIDENT PLACE, MOSQUITO WAY, HATFIELD, HERTFORDSHIRE, UNITED KINGDOM
Ph:440170-785-3000

Business Analysis of Mylan

The Life Sciences Sector is witnessing a major shakeup, new age business models in the industry are transforming both customers and businesses. Faced with this uncertainity, companies are investing resources to transform their business. An in-depth business analysis is a valuable resource to identify and articulate the need for a business model change. At R&P Research we believe, the starting point for a business analysis is Benchmarking. Business benchmarking can be done at various levels: 1) Industry Benchmarking 2) Peer Benchmarking 3) Disruptors Benchmarking. In this report, we share the snapshot of how Mylan compares against the industry on the major performance indicators. This analysis, along with peer group/disruptors benchmarking and revenue model understanding can help identify growth and cost optimization opportunities to maximize the value delivered by Mylan to its stakeholders. R&P Research Industry Intelligence Platform provides historical data for last 15 years with an easy to use benchmarking interface for an in-depth comparative business analysis.

Here is the performance snapshot of Mylan with an interactive chart.

  1. Revenue Growth: Mylan reported a revenue growth of 17.5% year-on-year during 2016. Pharmaceuticals Industry grew at 7.7% in the same period
  2. COGS share of Revenues: As a percentage of revenue, Mylan spent 57.6% of its total revenues on COGS. Pharmaceuticals industry average (COGS share of revenue) in the same period was 31.7%
  3. R&D share of Revenues: As a percentage of revenue, Mylan spent 7.5% of its total revenues on R&D. Pharmaceuticals industry average R&D spending in the same period was 15.6%
  4. SG&A share of Revenues: As a percentage of revenue, Mylan spent 22.5% of its total revenues on Sales, Marketing, and General Administration (SG&A). Pharmaceuticals industry average SG&A spending in the same period was 27.9%
  5. Inventory share of Revenues: As a percentage of revenue, Mylan spent 22.2% of its total revenues on Inventories. Pharmaceuticals industry average Inventory spending in the same period was 13.1%
  6. Accounts Payable share of Revenues: As a percentage of revenue, Mylan invested 12.2% of its total revenues on Accounts Payable (A/P) Pharmaceuticals industry average Accounts Payable investment in the same period was 12.4%
  7. Accounts Receivable share of Revenues: As a percentage of revenue, Mylan invested 29.9% of its total revenues on Accounts Receivable (A/R). Pharmaceuticals industry average Accounts Receivable investment in the same period was 19.0%
  8. PP&E share of Revenues: As a percentage of revenue, Mylan invested 21.0% of its total revenues on Property, Plants, and Equipments (PP&E). Pharmaceuticals industry average PPE investment in the same period was 26.2%
  9. Intangibles share of Revenues: As a percentage of revenue, Mylan invested 213.8% of its total revenues on Intangibles. Pharmaceuticals industry average Intangibles investment in the same period was 161.8%
  10. Net Margins: Mylan Net Margins in the year 2016 were 4.3%. Pharmaceuticals industry average Net Margins in the same period were 15.8%

Sector and Industry Association of Mylan

For the purpose of performance benchmarking of a company with a sector or industry average, R&P Research associates every company with one sector and one industry. An industry consists of companies with related/similar business models. A sector comprises of a group of related/similar industries. For high-level analysis purposes, related/similar sectors are grouped into sector groups.

Mylan is associated with Healthcare Sector Group, Life Sciences Sector, and Pharmaceuticals Industry.

Life Sciences sector is comprised of the following industries: Pharmaceuticals; Medical Devices; Biotechnology; Diagnostics & Scientific Instruments. The definitions for each of the industries is as follows:

  • Pharmaceuticals industry includes companies that discover, develop, manufacture, and market medicines licensed for use as medications. In general these companies offer pharmaceutical products that can be described as prescription or over-the-counter medicines. Many Pharmaceutical companies also offer a diverse portfolio of animal health products, services and solutions. Many diversified pharmaceutical companies operate in more than two operating segments like consumer health products, medical devices and pharmaceutical.
  • Medical Devices industry includes manufacturers and distributors of medical equipments and medical supplies. Medical equipments include large scale capital equipmets such as X-Ray machines and MRI scanners and other nondisposable medical devices like stents and pacemakers. Medical supplies include makers of contact lenses, eyeglass lenses, bandages and other disposable products.
  • Biotechnology industry includes Biotechnology product companies, subscription companies, and service companies. Biotechnology product companies offer pharmaceutical drug products that are manufactured in, extracted from, or semi synthesized from biological sources. Subscription-based companies develop genome databases, which can be used to develop medicinal drugs. Service companies offer solutions based on a common technology or generic tool of other large pharmaceutical or biopharmaceutical companies.
  • Diagnostics & Scientific Instruments industry includes companies that provide testing products, diagnostic reagents, instruments and diagnostic services to aid in the detection and treatment of a wide range of diseases. It also includes molecular diagnostic and genetic testing companies that develop, manufacture, market and provide diagnostic tests, diagnostic systems and related products and services. Also included are companies that manufacture and market analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics.

Industry Ranking of Mylan

With $11.1 billion revenues, Mylan ranked number 9 of all the companies in the US Pharmaceuticals industry. There were a total of 49 public companies in the US Pharmaceuticals industry that had revenues greater than $50 million during 2016.

The top-10 companies in the US Pharmaceuticals industry by revenues during 2016 were:

  1. J&J ($71.9 billion)
  2. Pfizer ($52.8 billion)
  3. Merck ($39.8 billion)
  4. Eli Lilly ($21.2 billion)
  5. Abbott Laboratories ($20.9 billion)
  6. Bristol Myers Squibb ($19.4 billion)
  7. Allergan ($14.6 billion)
  8. Shire ($11.4 billion)
  9. Mylan ($11.1 billion)
  10. Valeant Pharmaceuticals ($9.7 billion)

Business Model Analysis (BMA) Framework

We use the following framework to assess the business model of a company. Business Model Analysis framework can be used by organizations to articulate growth strategies and identify cost optimization opportunities. Technology and consulting companies can use this framework to identify the value drivers and pain points of their targeted customers. Entrepreneurs can use this framework to understand the language of business and identify promising business opportunities. This framework can be used by any professional aspiring to take up a leadership role to better understand the businesses challenges, articulate growth strategy, and monitor the business improvement requirements for the organization.

Next Steps

  • Conduct a holistic benchmarking; to identify and target additional sources of value
  • Get in touch with us to learn more about Business Model Analysis Framework
  • Get free data, charts, and analysis of Mylanand its peers on select key performance indicators by clicking the reports provided below

Industry Peers and Competitors of mylan

Bristol Myers Squibb (BMY) Business Analysis – Analyze Historical Performance, Strategic...

Bristol Myers Squibb Co with $19 billion revenues in the year 2016 was the number 6 Pharmaceuticals company. Read this report to know the top competitors of Bristol Myers Squibb and identify growth and cost optimization opportunities of Bristol Myers Squibb

Allergan (AGN) Business Analysis – Analyze Historical Performance, Strategic Priorities, And...

Allergan Plc with $15 billion revenues in the year 2016 was the number 7 Pharmaceuticals company. Read this report to know the top competitors of Allergan and identify growth and cost optimization opportunities of Allergan

Shire (SHPG) Business Analysis – Analyze Historical Performance, Strategic Priorities, And...

Shire Plc with $11 billion revenues in the year 2016 was the number 8 Pharmaceuticals company. Read this report to know the top competitors of Shire and identify growth and cost optimization opportunities of Shire

Valeant Pharmaceuticals (VRX) Business Analysis – Analyze Historical Performance, Strategic Priorities,...

Valeant Pharmaceuticals International, Inc. with $10 billion revenues in the year 2016 was the number 10 Pharmaceuticals company. Read this report to know the top competitors of Valeant Pharmaceuticals and identify growth and cost optimization opportunities of Valeant Pharmaceuticals

Zoetis (ZTS) Business Analysis – Analyze Historical Performance, Strategic Priorities, And...

Zoetis Inc. with $5 billion revenues in the year 2016 was the number 11 Pharmaceuticals company. Read this report to know the top competitors of Zoetis and identify growth and cost optimization opportunities of Zoetis

Endo International (ENDP) Business Analysis – Analyze Historical Performance, Strategic Priorities,...

Endo International Plc with $4 billion revenues in the year 2016 was the number 12 Pharmaceuticals company. Read this report to know the top competitors of Endo International and identify growth and cost optimization opportunities of Endo International

Revenues Analysis

Mylan (MYL) Revenues And Revenue Growth From 2012 To 2016

This report provides the last five years revenues and revenue growth of Mylan N.V. (MYL) from 2012 to 2016. Mylan generated a total of $11.1 billion revenues during 2016. Mylan reported a revenue growth of 17.5% year-over-year during 2016. The revenues and the revenue growth correspond to the fiscal year ending in December.

Mylan (MYL) Revenues And Revenue Growth From 2002 To 2016

This report provides the last fifteen years revenues and revenue growth of Mylan N.V. (MYL) from 2002 to 2016. Mylan generated a total of $11.1 billion revenues during 2016. Mylan reported a revenue growth of 17.5% year-over-year during 2016. The revenues and the revenue growth correspond to the fiscal year ending in December.

Mylan (MYL) Revenue Growth Comparison With Industry Growth From 2012 To...

This report provides a comparison of Mylan N.V. (MYL) revenue growth with Pharmaceuticals industry growth during the last five years from 2012 to 2016. Mylan reported a revenue growth of 17.5% year-over-year during 2016. The Pharmaceuticals industry growth was 7.7% year-over-year during 2016. Mylan growth was faster than the industry during 2016.

Profit Analysis